Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease.

• Tác giả: Rhonda Bohn, Adam de Havenon, Katherine Dea, Neil Dhopeshwarkar, Aaron King, Charles E Leonard, Xi Tan
• Ngôn ngữ: eng
• Thông tin xuất bản: Netherlands : American journal of preventive cardiology , 2025
• Bộ sưu tập: NCBI
• ID: 701596

Tóm tắt

INTRODUCTION: Limited data exist on the cardiovascular effectiveness of once-weekly (OW) glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in real-world practice. METHODS: We assessed the OW GLP-1 RA effects on vascular risk factors in adults with type 2 diabetes and atherosclerotic cardiovascular disease using data from a large-scale US electronic health record database (index date = first prescription of OW GLP-1 RA). Exploratory analyses were performed on patients newly initiating OW GLP-1 RAs with semaglutide, OW GLP-1 RAs without semaglutide, and semaglutide. Changes in vascular risk factors were evaluated by comparing mean measures between the 12-month pre- and post-index periods. Analyses were conducted for all three cohorts and subpopulations including stratified by tercile of baseline vascular risk factor value. RESULTS: In the final cohorts ([1] OW GLP-1 RA including semaglutide: CONCLUSION: Our data suggest GLP-1 RAs are associated with significant reductions in key vascular risk factors in real-world practice.